Tomas Philipson, PhD

Tomas Philipson, PhD, says historical reform efforts in the United States have raised doubts as to whether or not the implementation of the Affordable Care Act will slow health spending growth. Dr Philipson also suggests that concepts of value-based insurance design must be considered differently when managing a chronic condition like diabetes.

Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.